Terumo Blood and Cell Technologies collaborates with Eliaz Therapeutics in the development and commercialization of a novel therapeutic apheresis treatment for acute kidney injury (AKI)
Retrieved on:
Wednesday, July 27, 2022
Patient, National, NIH, Chronic kidney disease, CKD, International Society of Nephrology, McIntyre, Dialysis, IP, Incidence, Acute kidney injury, Hospital, Cell, Clinical trial, ICU, Death, Nephron, Critical Care (journal), International Society, SA, Fatty liver disease, Triple-negative breast cancer, Cancer, Technology, Lancet, Spectra, ROSA, Nephrology, ESRD, PLOS, GLOBE, Industry, RL, Software, Sepsis, Kidney, General manager, TSE, COVID-19, ETI, Blood, Quality of life, Survival, Neurology, Face, Plasma, J. Eliazer Stadion, Awareness, Veni, vidi, vici, Sickle cell disease, Health, TPE, Risk, Therapy, AKI, Inflammation, MD, Horizon Fuel Cell Technologies, Animal, Pharmaceutical industry, Terumo
Terumo Blood and Cell Technologies specializes in a portfolio of technology, software and services for blood component collection, therapeutic apheresis and cellular technologies.
Key Points:
- Terumo Blood and Cell Technologies specializes in a portfolio of technology, software and services for blood component collection, therapeutic apheresis and cellular technologies.
- Working with Terumo Blood and Cell Technologies could bring broad availability of this therapy to the global marketplace."
- Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices.
- Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.